JP6035578B2 - 乳酸菌、それを含む組成物及びそれらの使用 - Google Patents

乳酸菌、それを含む組成物及びそれらの使用 Download PDF

Info

Publication number
JP6035578B2
JP6035578B2 JP2015088066A JP2015088066A JP6035578B2 JP 6035578 B2 JP6035578 B2 JP 6035578B2 JP 2015088066 A JP2015088066 A JP 2015088066A JP 2015088066 A JP2015088066 A JP 2015088066A JP 6035578 B2 JP6035578 B2 JP 6035578B2
Authority
JP
Japan
Prior art keywords
composition
individual
lactic acid
acid bacterium
functional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015088066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015213501A (ja
JP2015213501A5 (enExample
Inventor
英傑 蔡
英傑 蔡
偉賢 劉
偉賢 劉
堅甫 廖
堅甫 廖
智捷 許
智捷 許
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Yang Ming Chiao Tung University NYCU
Original Assignee
National Yang Ming Chiao Tung University NYCU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/259,442 external-priority patent/US10967013B2/en
Priority claimed from US14/690,502 external-priority patent/US10188684B2/en
Application filed by National Yang Ming Chiao Tung University NYCU filed Critical National Yang Ming Chiao Tung University NYCU
Publication of JP2015213501A publication Critical patent/JP2015213501A/ja
Publication of JP2015213501A5 publication Critical patent/JP2015213501A5/ja
Application granted granted Critical
Publication of JP6035578B2 publication Critical patent/JP6035578B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
JP2015088066A 2014-04-23 2015-04-23 乳酸菌、それを含む組成物及びそれらの使用 Active JP6035578B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/259,442 2014-04-23
US14/259,442 US10967013B2 (en) 2014-04-23 2014-04-23 Lactic acid bacterium for prophylaxis or treatment of a stress-induced disorder and a composition containing the same
US14/690,502 2015-04-20
US14/690,502 US10188684B2 (en) 2015-04-20 2015-04-20 Method for preventing or treating functional gastrointestinal disorder by lactic acid bacterium

Publications (3)

Publication Number Publication Date
JP2015213501A JP2015213501A (ja) 2015-12-03
JP2015213501A5 JP2015213501A5 (enExample) 2016-01-28
JP6035578B2 true JP6035578B2 (ja) 2016-11-30

Family

ID=53008330

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015088066A Active JP6035578B2 (ja) 2014-04-23 2015-04-23 乳酸菌、それを含む組成物及びそれらの使用

Country Status (5)

Country Link
EP (1) EP2937424B1 (enExample)
JP (1) JP6035578B2 (enExample)
CN (1) CN105002109B (enExample)
ES (1) ES2624673T3 (enExample)
PL (1) PL2937424T3 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6933358B2 (ja) * 2016-04-06 2021-09-08 東海漬物株式会社 美肌促進剤
JP6878565B2 (ja) * 2016-07-19 2021-05-26 ベネド バイオメディカル カンパニー リミテッド 乳酸菌による大脳基底核疾患、または、チック障害を治療または予防するための薬剤
KR20180019474A (ko) * 2016-08-16 2018-02-26 주식회사 엠디헬스케어 락토바실러스 플란타룸 유래 소포를 포함하는 정신질환 예방 또는 치료용 조성물
CN107050062A (zh) * 2016-11-08 2017-08-18 江西益盟科技有限公司 治疗便秘的乳酸菌组合物及其制备方法
MY199866A (en) * 2017-01-13 2023-11-26 Bened Biomedical Co Ltd A novel lactic acid bacteria and its applications
KR102089836B1 (ko) * 2017-03-15 2020-03-16 (주)바이오일레븐 트립토판분해효소 음성균과 인터페론 감마 형성을 유도하는 균주를 이용한 염증성 질환 예방 및 치료용 약학적 조성물 또는 이를 이용한 치료방법
CN106906165B (zh) * 2017-04-25 2020-07-24 重庆第二师范学院 一种植物乳杆菌及其在制备预防便秘的食品中的应用
CN107267416A (zh) * 2017-07-05 2017-10-20 重庆第二师范学院 植物乳杆菌ys2及其在制备预防便秘的食品中的应用
WO2019119261A1 (en) * 2017-12-19 2019-06-27 Dupont Nutrition Biosciences Aps Probiotics for cognitive and mental health
US20200330531A1 (en) * 2017-12-19 2020-10-22 Dupont Nutrition Biosciences Aps Probiotics for cognitive and mental health
MX420836B (es) * 2018-02-02 2025-02-10 Kobiolabs Inc Cepa lactobacillus plantarum kbl396 y uso de la misma.
CN111035661A (zh) * 2018-10-15 2020-04-21 深圳市华大农业应用研究院 植物乳杆菌的用途
TWI731279B (zh) 2018-11-21 2021-06-21 葡萄王生技股份有限公司 發酵乳桿菌gkf3、含其之組合物及改善精神失調之用途
ES2763350B2 (es) * 2018-11-28 2020-10-13 Consejo Superior Investigacion Cepa de christensenella minuta y uso de la misma
JP2022511510A (ja) * 2018-12-06 2022-01-31 デュポン ニュートリション バイオサイエンシーズ エーピーエス 認知的健康及び精神的健康のためのプロバイオティクス
CN113302280B (zh) * 2019-01-28 2024-05-24 益福生医股份有限公司 保护个体运动的方法
EP3918055B9 (en) * 2019-02-01 2025-11-05 Bened Biomedical Co., Ltd. Method for preventing or treating abnormal emotion or behavior in non-human animal by lactic acid bacterium
WO2020157297A1 (en) * 2019-02-01 2020-08-06 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Lactococcus lactis strains for the prevention and/or the treatment of visceral pain
KR102148707B1 (ko) * 2019-02-22 2020-08-31 한국식품연구원 우울증 및 불안장애의 예방, 개선 또는 치료 효능을 갖는 김치 유산균 락토바실러스 사케아이
CN115052969A (zh) * 2020-02-06 2022-09-13 李旺祚 用于预防或治疗雷特氏综合征的乳酸菌组合物
US20230330163A1 (en) * 2020-03-25 2023-10-19 Bened Biomedical Co., Ltd. Method for reducing behavioral abnormalities
CN116367847A (zh) * 2020-10-22 2023-06-30 李旺祚 用于治疗芳香族l-氨基酸脱羧基酶缺乏症的乳酸菌
WO2022131192A1 (ja) * 2020-12-16 2022-06-23 株式会社明治 脳組織の炎症改善用組成物
CN113215018A (zh) * 2021-02-04 2021-08-06 郑州大学 一株植物乳杆菌植物亚种及其在豆粕和北艾混合发酵中的应用
CN113564084A (zh) * 2021-08-13 2021-10-29 华东理工大学 植物乳杆菌x7022在预防和治疗便秘上的应用
TWI810645B (zh) * 2021-09-06 2023-08-01 景岳生物科技股份有限公司 乳桿菌組合物及其改善抗生素造成之焦慮症的用途
KR20250095634A (ko) * 2022-10-28 2025-06-26 시에이치알. 한센 에이/에스 과민성 대장 증후군 증상 해결에 사용되기 위한 락티플란티바실러스 플란타룸
CN117143760B (zh) * 2023-07-12 2024-09-20 西南大学 一株能促进5-htp分泌及缓解抑郁的鼠李糖乳酪杆菌ky16及其应用
KR102741129B1 (ko) * 2023-11-07 2024-12-11 농업회사법인 고려홍삼원 주식회사 락토바실러스 플란타룸 ckh-01 균주를 포함하는 스트레스 완화 및 수면개선용 프로바이오틱스 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725853A (en) * 1994-10-18 1998-03-10 Pioneer Hi-Bred International, Inc. 4 strain direct-fed microbial
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
JP5400779B2 (ja) * 2008-08-21 2014-01-29 サントリーホールディングス株式会社 セロトニントランスポーター阻害活性を有する医薬品又は飲食品

Also Published As

Publication number Publication date
EP2937424A1 (en) 2015-10-28
EP2937424B1 (en) 2017-03-29
PL2937424T3 (pl) 2017-09-29
ES2624673T3 (es) 2017-07-17
JP2015213501A (ja) 2015-12-03
CN105002109B (zh) 2018-09-14
CN105002109A (zh) 2015-10-28

Similar Documents

Publication Publication Date Title
JP6035578B2 (ja) 乳酸菌、それを含む組成物及びそれらの使用
KR101813881B1 (ko) 락트산 박테리아, 이를 함유하는 조성물 및 그의 용도
Visñuk et al. Neuroprotective effects associated with immune modulation by selected lactic acid bacteria in a Parkinson's disease model
Ng et al. A meta-analysis of the use of probiotics to alleviate depressive symptoms
Rieder et al. Microbes and mental health: A review
Roškar et al. Effects of a probiotic product containing Bifidobacterium animalis subsp. animalis IM386 and Lactobacillus plantarum MP2026 in lactose intolerant individuals: Randomized, placebo-controlled clinical trial
JP2019135254A (ja) 細菌株を含む組成物
Zoll et al. Fecal microbiota transplantation from high caloric-fed donors alters glucose metabolism in recipient mice, independently of adiposity or exercise status
CA3162695A1 (en) Compositions comprising microbes and methods of use and making thereof
Ivashkin et al. A correction of a gut microflora composition for the allergic bronchial asthma complex therapy
US11058733B2 (en) Active substances of Bifidobacterium lactis GKK2, composition comprising the same and method of promoting longevity using the same
CN117018040B (zh) 动物双歧杆菌乳亚种在神经保护中的应用
Kim et al. Investigation of memory-enhancing effects of Streptococcus thermophilus EG007 in mice and elucidating molecular and metagenomic characteristics using nanopore sequencing
Tanner et al. Current and future uses of probiotics
WO2022192854A1 (en) Methods to induce biopterin and related metabolites
US12419920B2 (en) Bifidobacterium longum NCIMB 41676
US20200289588A1 (en) Bifidobacterium longum ncimb 41676
Chen et al. The human microbiota and its therapeutic options
US11813296B2 (en) Bacillus subtilis probiotics and methods of use for improving immune function, hormonal status, and physical performance
Roos et al. Therapeutic Value of Lactobacillus gasseri 345A in Chronic Constipation
Liu et al. Effects of exercise intervention on intestinal flora in college students: a systematic review
Ivanova et al. Human Gut Microbiome as an Indicator of Human Health
Genc et al. Investigation of the intestinal flora from the Ruminococcaceae family in sportsmen and sedentary men
Dean Cultivating Excellence: A Literature Review on Harnessing the Power of the Gut Microbiome for Athletic Performance
Kirchgessner The role of the microbiota and potential for dietary intervention in chronic fatigue syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161005

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161007

R150 Certificate of patent or registration of utility model

Ref document number: 6035578

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250